Shares of Gilead Sciences Inc. GILD shed 1.67% to $90.59 Monday, on what proved to be an all-around dismal trading session ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

A drug used to treat HIV that has also shown promise in preventing infections is not a cure for those already infected, as ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

For years, Gilead Sciences was dead money for shareholders. Shares of the drugmaker, with a market capitalization of just ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

December 1st has been declared Carlton Smith Day in Baltimore City, honoring Smith's advocacy for LGBTQ+ and HIV-affected ...

In a report released today, Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc.

Pharma company Gilead Sciences has been awarded a massive $31.8 million in damages in connection with a lawsuit claiming ...